Malik Prabhat Singh, Malik Anita, Deo Suryanarayana Venkata, Mohan Anant, Mohanti Bidhu Kalyan, Raina Vinod
Departments of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India E-mail :
Asian Pac J Cancer Prev. 2014;15(6):2875-8. doi: 10.7314/apjcp.2014.15.6.2875.
Lung cancer is one of the commonest and most lethal cancers throughout the world. The majority of the patients present at advance stage and are not suitable for curative intent treatment. Even among patients with localized disease, there has been underutilization of curative treatment modalities. The aim of this study was to analyze the radical treatment utilization rates in patients with non small cell lung cancer (NSCLC) treated at our centre.
We analyzed case records of 104 patients with a pathologically confirmed diagnosis of NSCLC having stage 1-3B disease who were treated at our centre over last 3 years, to assess the utilization of curative treatment modalities i.e. surgery or radical radiotherapy.
The median age of this cohort was 58 years. Out of 104 patients only 33 (31.7%) received curative intent treatment, 14 undergoing curative resection and 19 receiving radical doses of radiotherapy. The baseline characteristics of both the groups (with or without radical treatment) were not different. Major factors associated with underutilization with curative treatment were progressive disease or loss of follow up after chemotherapy and inappropriate use of TKI and/ or palliative radiotherapy in patients with stage 1-3B disease. Patients who did not receive radical treatment had inferior PFS and OS than those who received radical treatment.
In our practice we observed gross underutilization of curative intent treatment modalities in patients with NSCLCs which is associated with inferior survival.
肺癌是全球最常见且最致命的癌症之一。大多数患者就诊时已处于晚期,不适合进行根治性治疗。即使在局限性疾病患者中,根治性治疗方式的使用也不足。本研究的目的是分析在我们中心接受治疗的非小细胞肺癌(NSCLC)患者的根治性治疗利用率。
我们分析了过去3年在我们中心接受治疗的104例经病理确诊为1-3B期NSCLC患者的病例记录,以评估根治性治疗方式即手术或根治性放疗的使用情况。
该队列的中位年龄为58岁。在104例患者中,只有33例(31.7%)接受了根治性治疗,14例接受了根治性切除,19例接受了根治性放疗剂量。两组(接受或未接受根治性治疗)的基线特征无差异。根治性治疗使用不足的主要相关因素是化疗后疾病进展或失访,以及1-3B期疾病患者不适当使用TKI和/或姑息性放疗。未接受根治性治疗的患者的无进展生存期(PFS)和总生存期(OS)低于接受根治性治疗的患者。
在我们的实践中,我们观察到NSCLC患者根治性治疗方式的使用严重不足,这与较差的生存率相关。